OBJECTIVES:  Cognitive dysfunction is an important dimension of Major Depressive Disorder (MDD). However, few studies have assessed the relationship between cognitive dysfunction and workplace productivity. AtWoRC (Assessment in Work productivity and the Relationship with Cognitive symptoms in patients with MDD taking vortioxetine; NCT02332954) is an interventional, open-label, Canadian study designed to assess the association between cognitive symptoms and work productivity in gainfully employed patients with MDD receiving vortioxetine. METHODS:  Patients diagnosed with MDD were prescribed vortioxetine and assessed over a total of 52 weeks at routine care visits that emulated a real-life setting. Patients were classified as having not been treated with another antidepressant (first treatment) or having inadequate response to a previous antidepressant (switch). The primary endpoint is partial correlation between changes in patient-reported cognitive symptoms (20-item Perceived Deficits Questionnaire; PDQ-D-20) scores and self-reported work productivity loss (Work Limitations Questionnaire; WLQ) scores over 12 weeks of vortioxetine treatment. Additional assessments include changes in symptom and disease severity, functioning, pharmacoeconomics, and safety and tolerability. Data presented here is from the primary analysis at Week 12; the study is currently ongoing. RESULTS:  As of November 2016, 196 eligible patients (97 first treatment, 99 switch) at 26 sites were enrolled, received at least one treatment dose, and attended at least one post-baseline study visit. Primary analysis at Week 12 indicated a significant correlation between PDQ-D-20 and WLQ scores (r = 0.633; p<0.001). The correlation between PDQ-D-20 and WLQ scores was comparable and significant in both first treatment (r = 0.671; p<0.001) and switch patients (r = 0.584; p<0.001). Safety and tolerability were consistent with the Canadian Product Monograph for vortioxetine. CONCLUSIONS: After 12 weeks of treatment with vortioxetine, improvements in self-reported cognitive dysfunction were significantly associated with improvements in self-reported workplace productivity in Canadian patients with MDD.